elranatamab
Sponsor Pfizer INC · listed as PFE
READOUT
Phase 3
Confidence: medium
Source: clinicaltrials
Next catalyst
Event typeREADOUT
Expected date2026-08-30
As disclosedAug 30, 2026
Date precisionday
Confidencemedium
Trial & sponsor
Trial (NCT)NCT06152575
PhasePHASE3
StatusRECRUITING
Lead sponsorPfizer
Listed asPFE
Condition(s)Multiple Myeloma
All tracked catalysts for elranatamab
| Date | Event | Confidence | Trial |
|---|---|---|---|
| 2026-08-30 | READOUT | medium | NCT06152575 |
| 2027-08-04 | READOUT | medium | NCT05317416 |
!
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This is one row of the free CSA sample. The full snapshot carries 2,103 forward catalysts across 139 listed sponsors.
Get the full dataset — $499 → More PFE catalysts